<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617522</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-132-15</org_study_id>
    <nct_id>NCT04617522</nct_id>
  </id_info>
  <brief_title>Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to identify the safe starting dose of sacituzumab&#xD;
      govitecan-hziy, assess the number of participants with antibodies against sacituzumab&#xD;
      govitecan-hziy, and evaluate the pharmacokinetics (PK) of sacituzumab govitecan-hziy, free&#xD;
      SN-38, SN-38 glucuronide (SN-38G), total SN-38, in participants with solid tumor and moderate&#xD;
      hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>First dose date up to Day 38</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Any Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>First dose date up to Day 38</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy</measure>
    <time_frame>Days 1 and 8</time_frame>
    <description>Cmax will be determined for 4 analytes: Free SN-38, SN-38 glucuronide, Total SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. Cmax is defined as the maximum observed concentration obtained directly from the observed concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUC_0-last of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy</measure>
    <time_frame>Days 1 and 8</time_frame>
    <description>AUC_0-last was determined for 4 analytes: Free SN-38, SN-38 glucuronide, Total SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC_0-last is defined as area under the serum concentration-time curve from time 0 to time of the last quantifiable concentration of the 4 analytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUC_0-168 of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy</measure>
    <time_frame>Days 1 and 8</time_frame>
    <description>AUC_0-168 was determined for 4 analytes: Free SN-38, SN-38 glucuronide, Total SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-168 is defined as area under the serum concentration-time curve from time 0 to 168 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies</measure>
    <time_frame>Day 1 (Predose) and Day 22</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Advanced or Metastatic Solid Tumor</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Advanced or Metastatic Solid Tumor and Moderate Liver Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced or Metastatic Solid Tumor and Normal Liver function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan-hziy</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Advanced or Metastatic Solid Tumor and Moderate Liver Impairment</arm_group_label>
    <arm_group_label>Advanced or Metastatic Solid Tumor and Normal Liver function</arm_group_label>
    <other_name>IMMU-132</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria for all Individuals:&#xD;
&#xD;
          -  Histologically confirmed advanced or metastatic solid tumor that is measurable or&#xD;
             nonmeasurable.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.&#xD;
&#xD;
          -  Adequate hematologic counts without transfusional or growth factor support within 2&#xD;
             weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC)&#xD;
             ≥1,500/mm^3, and platelets ≥ 100,000/ μL).&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation&#xD;
&#xD;
        Key Inclusion Criteria for Individuals with Normal Hepatic Function:&#xD;
&#xD;
          -  Normal hepatic function (total bilirubin ≤ ULN and aspartate aminotransferase [AST] ≤&#xD;
             3.0× ULN).&#xD;
&#xD;
        Key Inclusion Criteria for Individuals with Moderate Hepatic Function:&#xD;
&#xD;
          -  Moderate hepatic impairment (1.5 × ULN &lt; total bilirubin &lt; 3.0 × ULN and any level of&#xD;
             AST).&#xD;
&#xD;
          -  For individuals with hepatic encephalopathy, the condition does not, in the&#xD;
             Investigator's opinion, interfere with the individual's ability to provide an&#xD;
             appropriate informed consent.&#xD;
&#xD;
        Key Exclusion Criteria for all Individuals:&#xD;
&#xD;
          -  Have poor venous access&#xD;
&#xD;
          -  Donated or lost 500mL or more of blood volume (including plasmapheresis) to plans to&#xD;
             donate during the study&#xD;
&#xD;
          -  Have had a prior anticancer biologic agent within 4 weeks prior to Day 1 or have had&#xD;
             prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2&#xD;
             weeks prior to Day 1 and who have not recovered (i.e., ≤ Grade 2) from adverse events&#xD;
             (AEs) at the time of study entry. Individuals participating in observational studies&#xD;
             are eligible.&#xD;
&#xD;
          -  Had prior treatment with irinotecan within 4 weeks prior to Day 1&#xD;
&#xD;
          -  Have not recovered (i.e., ≤ Grade 1) from AEs due to a previously administered agent&#xD;
&#xD;
          -  Have an active second malignancy&#xD;
&#xD;
          -  Have known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Individuals with previously treated brain metastases may participate&#xD;
             provided they have stable CNS disease for at least 4 weeks prior to the first dose of&#xD;
             study drug and all neurologic symptoms have returned to baseline, have no evidence of&#xD;
             new or enlarging brain metastases, and are taking ≤ 20 mg/day of prednisone or its&#xD;
             equivalent. All individuals with carcinomatous meningitis are excluded regardless of&#xD;
             clinical stability.&#xD;
&#xD;
          -  Have history of cardiac disease&#xD;
&#xD;
          -  Have active chronic inflammatory bowel disease (ulcerative colitis or Crohn's disease)&#xD;
             or gastrointestinal (GI) perforation within 6 months of enrollment&#xD;
&#xD;
          -  Have active serious infection requiring intravenous antibiotics (Contact medical&#xD;
             monitor for clarification)&#xD;
&#xD;
          -  High-dose systemic corticosteroids (≥20 mg of prednisone or its equivalent) are not&#xD;
             allowed within 2 weeks of Check-In. However, inhaled, intranasal, intra-articular, and&#xD;
             topical steroids are allowed.&#xD;
&#xD;
          -  Use of strong inhibitor or inducer of UGT1A1&#xD;
&#xD;
          -  Have a history of Gilbert's disease&#xD;
&#xD;
        Key Exclusion Criteria for Individuals with Normal Hepatic Impairment:&#xD;
&#xD;
          -  Must have pre-existing condition interfering with hepatic and/or renal function that&#xD;
             could interfere with the metabolism and/or excretion of the study drug&#xD;
&#xD;
        Key Exclusion Criteria for Individuals with Moderate Hepatic Impairment:&#xD;
&#xD;
          -  Had a clinical exacerbation of liver disease within the 2-week period before&#xD;
             administration of study drug (i.e., abdominal pain, nausea, vomiting, anorexia, or&#xD;
             fever)&#xD;
&#xD;
          -  Had clinically demonstrable, tense ascites&#xD;
&#xD;
          -  Had evidence of acute viral hepatitis within 1 month prior to administration of study&#xD;
             drug&#xD;
&#xD;
          -  Have evidence of hepatorenal syndrome&#xD;
&#xD;
          -  Individuals with transjugular intrahepatic portosystemic shunt (TIPS) placement.&#xD;
&#xD;
          -  Have active Stage 3 or 4 encephalopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=IMMU-132-15</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. doi: 10.1158/1078-0432.CCR-10-2939. Epub 2011 Mar 3.</citation>
    <PMID>21372224</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.</citation>
    <PMID>25915780</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.</citation>
    <PMID>28069724</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 8;6(26):22496-512. Erratum in: Oncotarget. 2020 Mar 10;11(10):942.</citation>
    <PMID>26101915</PMID>
  </reference>
  <reference>
    <citation>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.</citation>
    <PMID>1244564</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

